Ellie Collins

The theme of this year’s World Orphan Drug Congress (WODC) Europe was ‘strategy, advocacy and partnering for the world of orphan drugs and rare diseases’, which offered a great opportunity for Oxford PharmaGenesis to showcase our experience in the area of patient engagement.

Oxford PharmaGenesis were thrilled to be in Vienna earlier this month to take part in the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), which this year focused on ‘managing access to medical innovation: strengthening the methodology–policy nexus’.

Oxford PharmaGenesis insights into best practices for the planning and communication of real-world evidence (RWE) studies have been highlighted in an invited editorial, published online in the Journal of Comparative Effectiveness Research (http://www.futuremedicine.com/doi/full/10.2217/cer-2016-0070).

On 17–18 October, more than a hundred patients, patient advocates and representatives from pharma gathered in London, UK, for the 13th Annual eyeforpharma Patient Summit Europe to discuss the importance of patient centricity in the pharmaceutical industry.

Oxford PharmaGenesis was delighted to attend the Medical Affairs Leaders Forum in London, UK on 18–20 October. This meeting brought together medical affairs professionals and related industry staff and academics from Europe and beyond for 3 days of presentations, discussions and networking.

14­–17 September 2016, London, UK These are exciting times in the field of multiple sclerosis (MS) management; the past 5 years have seen an explosion in the number of disease-modifying therapies (DMTs) licensed for the treatment of patients with relapsing–remitting MS (RRMS).

The 2016 Medical Affairs Strategic Summit (MASS) West began on 14 September in San Diego, California, USA. The 3-day summit hosted professionals involved in all aspects of medical affairs including clinical research, health economics, key opinion leadership, medical communications and publication planning.

Oxford PharmaGenesis insights into patient-reported outcomes (PROs), health literacy and patient-centricity were the subject of the September edition of the International Society for Medical Publication Professionals (ISMPP) online education series, ISMPP University (ISMPP U).